BridgeBio Pharma, Inc. (BBIO) Q1 2023 Earnings Results

BridgeBio Pharma Misses on EPS — Stock Down 6.25%

The earnings report indicates that BridgeBio Pharma is facing challenges, as evidenced by the EPS miss. The stock's 6.25% decline reflects investor concern over the company's current performance and lack of guidance. Without clear direction, investors may remain cautious in the near term.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.92	N/A	-9.26%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Overall, management expressed caution regarding the current market conditions. They highlighted the importance of adapting strategies to navigate these challenges.

Management acknowledged ongoing challenges in the market.

They emphasized the need for strategic adjustments moving forward.

BridgeBio Pharma Misses on EPS — Stock Down 6.25%

Key numbers

Management commentary

BridgeBio Pharma, Inc.

More earnings this week

BridgeBio Pharma Misses on EPS — Stock Down 6.25%

Key numbers

Management commentary